United Therapeutics (UTHR) reported $794.4 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 17.2%. EPS of $6.63 for the same period compares to $6.17 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $726.19 million, representing a surprise of +9.39%. The company delivered an EPS surprise of +5.41%, with the consensus EPS estimate being $6.29.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how United Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- United States: $749.60 million compared to the $695.02 million average estimate based on three analysts. The reported number represents a change of +16.9% year over year.
• Revenues- Rest-of-World: $44.80 million compared to the $27.05 million average estimate based on three analysts. The reported number represents a change of +23.8% year over year.
• Revenue- Tyvaso- U.S. $441.10 million compared to the $405.30 million average estimate based on two analysts.
• Revenue- Remodulin- U.S. $120.20 million versus $113.15 million estimated by two analysts on average.
• Revenues- Adcirca: $6 million compared to the $4.77 million average estimate based on seven analysts. The reported number represents a change of -6.3% year over year.
• Revenues- Orenitram: $120.70 million versus the seven-analyst average estimate of $111.47 million. The reported number represents a year-over-year change of +13.7%.
• Revenues- Tyvaso: $466.30 million versus the six-analyst average estimate of $413.63 million. The reported number represents a year-over-year change of +105%.
• Revenues- Remodulin: $138.20 million compared to the $126.42 million average estimate based on six analysts. The reported number represents a change of +8% year over year.
• Revenues- Unituxin: $58.20 million versus the six-analyst average estimate of $62.95 million. The reported number represents a year-over-year change of -0.3%.
• Revenue- Tyvaso DPI: $302.50 million compared to the $271.57 million average estimate based on five analysts.
• Revenue- Nebulized Tyvaso: $163.80 million versus $137.44 million estimated by five analysts on average.
• Revenues- Other products: $5 million versus $5.68 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -19.4% change.

View all Key Company Metrics for United Therapeutics here>>>

Shares of United Therapeutics have returned -2% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

United Therapeutics Corporation (UTHR) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research